Skip to main content

Table 1 Clinical characteristics and laboratory data for patients

From: Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis

  Baseline Follow-up
  Anti-CRP-positive Anti-CRP-negative Mann-Whitney Anti-CRP-positive Anti-CRP-negative Mann-Whitney
Age (years) 30.5 (13.1) 35.0 (11.6) NS 27.0 (8.2) 35.1 (12.7) NS
Gender       
   Female 16 18   5 29  
   Male 1 3   1 3  
Ethnicity       
   Caucasian 16 17   5 28  
   Iranian Caucasian 0 3   0 3  
   Iraqi Caucasian 0 1   0 1  
   Asian 1 0   1 0  
Creatinine (μmol/l) 95.3 (43.3) 97.0 (51.0) NS 78.3 (9.6) 83 (46.2) NS
Albuminuria (g/day) 1.7 (1.4) 2.7 (2.3) NS 1.6 (1.3) 0.8 (0.9) NS
C3 (g/l) 0.47 (0.26) 0.57 (0.24) NS 0.85 (0.28) 0.80 (0.27) NS
C4 (g/l) 0.09 (0.06) 0.10 (0.05) NS 0.14 (0.03) 0.14 (0.07) NS
C1q (% of normal reference) 57.9 (37.3) 79.0 (36.7) NS 73.0 (32.4) 83.0 (28.1) NS
Anti-dsDNA-positive 16 18   3 21  
CLIFT titre, median 200 25 P = 0.04 25 10 NS
Renal histopathology       
   Class I 0 0   0 1  
   Class II 0 0   1 13  
   Class III 1 7   1 2  
   Class IV 12 7   2 4  
   Class III to IV/V 1 2   0 2  
   Class V 3 5   2 10  
Activity index 7.0 (3.1) 5.5 (3.5) NS 3.5 (2.0) 2.7 (3.2) NS
Chronicity index 2.3 (1.9) 1.4 (2.0) NS 2.7 (1.0) 2.7 (2.4) NS
BILAG index       
   A 14 20   1 5  
   B 3 1   4 14  
   C 0 0   0 8  
   D 0 0   1 5  
Treatment       
   Prednisolone, mean daily dose (mg) 10.1 (10.5) 12.9 (17.8) NS 14.5 (7.2) 10.6 (5.0) NS
   Mycophenolate mofetil 1 2     
   Cyclophosphamide 15 13     
   Rituximab 0 6     
   Mycophenolate mofetil/cyclophosphamide 1 0     
  1. Data presented as mean (standard deviation) or n. BILAG, British Isles Lupus Assessment Group; CLIFT, Crithidia luciliae immunofluorescence microscopy test; CRP, C-reactive protein; NS, not significant.